On the other hand, medications known as glucagon-like peptide-1 (GLP-1) agonists, also referred to as GLP-1 receptor agonists, incretin mimetics or GLP-1 analogs, are used to manage type 2 diabetes mellitus and, in some instances, obesity. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.